Cefepime Dosing for Aspiration Pneumonia
For aspiration pneumonia requiring broad-spectrum coverage, administer cefepime 2 g IV every 8 hours as the standard dose, with mandatory renal function-based adjustments to prevent neurotoxicity while maintaining efficacy.
Standard Dosing in Normal Renal Function
For patients with creatinine clearance (CrCl) >60 mL/min and moderate-to-severe pneumonia, cefepime 2 g IV every 8 hours is the recommended regimen 1, 2. This dosing provides optimal coverage for common pathogens in aspiration pneumonia including S. pneumoniae, K. pneumoniae, Enterobacter species, and P. aeruginosa when present 1.
- Administer as an intravenous infusion over approximately 30 minutes 2
- Treatment duration: typically 7-10 days 1, 2
- Consider extended 3-hour infusions for critically ill patients or infections with higher MIC organisms 3, 4
The 2016 IDSA/ATS guidelines specifically list cefepime 2 g IV q8h as a preferred empiric option for hospital-acquired pneumonia, which shares similar pathogen profiles with aspiration pneumonia 1. Research confirms this regimen is as effective as meropenem for moderate-to-severe aspiration pneumonia 5.
Renal Impairment Adjustments (Critical)
Dose adjustment based on CrCl is mandatory to prevent cefepime accumulation and neurotoxicity 2, 6:
Dosing Algorithm by Creatinine Clearance:
- CrCl >120 mL/min (augmented renal clearance): Consider 2 g every 6 hours 7
- CrCl 60-120 mL/min: 2 g every 8 hours (standard dose) 2
- CrCl 30-60 mL/min: 2 g every 12 hours 2
- CrCl 11-29 mL/min: 2 g every 24 hours 2
- CrCl <11 mL/min: 1 g every 24 hours 2
Special Populations:
Hemodialysis patients: 1 g on day 1, then 500 mg every 24 hours (or 1 g every 24 hours for severe infections), administered after dialysis 2
CAPD patients: 2 g every 48 hours 2
CRRT patients: For effluent rates <3.5 L/h, use 2 g every 12 hours as 4-hour infusions; for rates ≥3.5 L/h, use 2 g every 8 hours 8
Critical Safety Considerations
Neurotoxicity Risk
Cefepime has significant neurotoxic potential, particularly in renal impairment 6, 9. Even with dose adjustments, patients with CrCl <30 mL/min can accumulate toxic levels (trough concentrations 20-30 mg/L), manifesting as confusion, muscle jerks, or non-convulsive seizures 6.
Key warning signs:
- Confusion or altered mental status
- Myoclonus (muscle jerks)
- Seizures
- These symptoms may be subtle and attributed to other causes initially 6
Therapeutic Drug Monitoring
Consider TDM in high-risk situations:
- CrCl <50 mL/min, especially <30 mL/min 6
- Elderly patients (>65 years) 10
- Critically ill ICU patients 9
- When treating organisms with MIC ≥8 mg/L 6, 4
Target trough concentrations: Keep below 20 mg/L to minimize neurotoxicity risk while maintaining efficacy 6. Obtain TDM within 24-48 hours of treatment initiation when possible, as delayed results (>48 hours) are associated with higher rates of neurotoxicity (57.4% vs 24%) 9.
Augmented Renal Clearance Considerations
In younger critically ill patients with sepsis, augmented renal clearance (CrCl >150 mL/min) may lead to subtherapeutic levels with standard dosing 7, 9. In these patients:
- Age >33 years is a risk factor for overexposure even with ARC 9
- Consider 2 g every 6 hours for CrCl >120 mL/min 7
- Sepsis itself may be protective against overexposure 9
Combination Therapy Considerations
For aspiration pneumonia, anaerobic coverage is NOT routinely required unless lung abscess or empyema is suspected 11. When anaerobic coverage is needed, add metronidazole rather than switching from cefepime 1, 2.
For MRSA risk factors (prior IV antibiotics within 90 days, high local prevalence), add vancomycin 15 mg/kg IV q8-12h or linezolid 600 mg IV q12h 1.